{
  "meta": {
    "title": "Targeted_Anti-Cancer_Drugs",
    "url": "https://brainandscalpel.vercel.app/targeted-anti-cancer-drugs-c9fdeb77.html",
    "scrapedAt": "2025-11-29T18:33:33.045Z"
  },
  "questions": [
    {
      "id": 10896,
      "choices": [
        {
          "id": 43550,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Used in non-small cell carcinoma of lung</span></span></span></p>"
        },
        {
          "id": 43551,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is a small molecule tyrosine kinase inhibitor acting as EGFR antagonist</span></span></span></p>"
        },
        {
          "id": 43552,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Food decreases absorption</span></span></span></p>"
        },
        {
          "id": 43553,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It causes skin rashes and diarrhoea</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All are true about Erlotinib except?</span></span></span></p>",
      "unique_key": "Q6236379",
      "question_audio": null,
      "question_video": null,
      "map_id": 36479,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Food decreases absorption</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Erlotinib</strong> is a <strong>drug</strong> used primarily in the treatment of <strong>non-small cell lung carcinoma and pancreatic carcinoma, </strong>specifically when <strong>combined</strong> with<strong> gemcitabine</strong>. It functions as a <strong>tyrosine kinase inhibitor </strong>targeting the<strong> epidermal growth factor receptor (EGFR)</strong>, which is significant in the <strong>pathogenesis of various cancers.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Contrary to the statement in <strong>option C, food </strong>actually<strong> increases the absorption of Erlotinib,</strong> not decreases it. Studies indicate that the presence of<strong> food can increase the absorption of Erlotinib </strong>by approximately <strong>100%,</strong> suggesting that how <strong>Erlotinib </strong>is <strong>administered</strong> in <strong>relation to meals </strong>can significantly affect <strong>its efficacy.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Used in non-small cell carcinoma of lung:</span></strong><span style=\"font-size:12.0pt\"> This statement is<strong> correct.</strong> Erlotinib is indeed used for treating<strong> non-small cell lung carcinoma</strong>, acting primarily by <strong>inhibiting the EGFR pathways</strong> involved in <strong>cancer cell proliferation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. It is a small molecule tyrosine kinase inhibitor acting as EGFR antagonist:</span></strong><span style=\"font-size:12.0pt\"> This is also<strong> true</strong>. Erlotinib<strong> inhibits</strong> the <strong>activity of</strong> the<strong> EGFR</strong>, which is a <strong>tyrosine kinase, </strong>thereby interfering with the<strong> growth and survival of cancer cells.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. It causes skin rashes and diarrhoea:</span></strong><span style=\"font-size:12.0pt\"> Accurate as well. The most<strong> common adverse effects</strong> associated with <strong>Erlotinib</strong> include an <strong>acneiform skin rash and diarrhea</strong>, along with <strong>other side effects</strong> like<strong> anorexia and fatigue.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Erlotinib </strong>is a <strong>tyrosine kinase inhibitor</strong> used notably for<strong> non-small cell lung carcinoma and pancreatic carcinoma</strong>. Additionally, the <strong>absorption of Erlotinib </strong>is<strong> increased by food, </strong>which is an important consideration for its clinical use.</span></span></span></p>",
      "correct_choice_id": 43552,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10901,
      "choices": [
        {
          "id": 43570,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peripheral neuropathy</span></span></span></p>"
        },
        {
          "id": 43571,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diarrhea</span></span></span></p>"
        },
        {
          "id": 43572,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Teratogenicity</span></span></span></p>"
        },
        {
          "id": 43573,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Deep vein thrombosis</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thalidomide was once used for treating the emesis of pregnancy. Later, it was withdrawn from the market due to its side effects. However, it was reintroduced for certain indications like multiple myelomA. Which of the following is not a side effect of thalidomide?</span></span></span></p>",
      "unique_key": "Q8084760",
      "question_audio": null,
      "question_video": null,
      "map_id": 36480,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Diarrhea</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Thalidomide</strong> is <strong>notorious </strong>for its<strong> initial use</strong> during<strong> pregnancy </strong>to <strong>treat nausea and vomiting</strong>, but it was <strong>rapidly withdrawn</strong> due to <strong>severe teratogenic effects</strong> that resulted in <strong>substantial birth defects</strong>. It has since been <strong>reintroduced, </strong>especially for the<strong> treatment of</strong> <strong>diseases</strong> such as <strong>multiple myeloma </strong>due to its<strong> immunomodulatory effects. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Thalidomide</strong> is <strong>known to cause constipation</strong> rather than diarrhea, which aligns with its common gastrointestinal side effects, contrasting with the<strong> incorrect option</strong> that suggests it<strong> causes diarrhea. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Other</strong> notable<strong> adverse effects of thalidomide</strong> include <strong>peripheral neuropathy,</strong> where patients experience <strong>sensory changes</strong> like <strong>numbness or tingling in the extremities</strong>. Its<strong> teratogenic</strong> potential is<strong> highly</strong> significant, <strong>leading to severe limb </strong>and <strong>organ deformities</strong> when taken<strong> during pregnancy</strong>. Additionally,<strong> thalidomide increases </strong>the <strong>risk of thromboembolic </strong>events such as <strong>deep vein thrombosis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Peripheral neuropathy:</span></strong><span style=\"font-size:12.0pt\"> Accurately listed as a <strong>side effect</strong>, it involves<strong> nerve damage </strong>resulting in<strong> pain, numbness, or tingling</strong> <strong>sensations, </strong>primarily in the<strong> hands and feet.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Teratogenicity:</span></strong><span style=\"font-size:12.0pt\"> <strong>Correctly</strong> identified as a <strong>side effect</strong>, <strong>thalidomide</strong> causes <strong>severe birth defects,</strong> a major reason for its <strong>initial</strong> <strong>market withdrawal.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Deep vein thrombosis:</span></strong><span style=\"font-size:12.0pt\"> This is a<strong> valid side effect</strong>, with thalidomide <strong>increasing the risk for blood clots,</strong> necessitating <strong>caution and preventive </strong>measures in </span></span></span><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>its administration.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Major adverse effects of thalidomide:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Teratogenicity:</strong> <strong>Thalidomide</strong> is associated with<strong> severe birth defects</strong>, particularly <strong>limb abnormalities,</strong> when taken <strong>during</strong> <strong>pregnancy.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Peripheral neuropathy</strong>: Thalidomide can cause <strong>nerve damage</strong> that results in <strong>tingling, numbness, or pain </strong>in the <strong>hands</strong> <strong>and feet.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Thromboembolism</strong>: Thalidomide use is associated with an <strong>increased risk of blood clots,</strong> including <strong>deep vein thrombosis</strong> and<strong> pulmonary embolism.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Somnolence</strong>: Thalidomide can cause <strong>drowsiness or sedation</strong>, which may<strong> impair the ability </strong>to <strong>perform tasks</strong> that require <strong>alertness.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Bradycardia:</strong> Thalidomide may <strong>cause a slow heart rate</strong>, which can lead to <strong>dizziness or fainting.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Constipation</strong>: Thalidomide can cause <strong>gastrointestinal symptoms such as constipation, nausea, and vomiting.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Hypersensitivity reactions</strong>: Thalidomide can cause<strong> allergic reactions</strong>, including <strong>rash, itching, and difficulty breathing.</strong></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 43571,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10916,
      "choices": [
        {
          "id": 43630,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Erlotinib</span></span></span></p>"
        },
        {
          "id": 43631,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ribociclib </span></span></span></p>"
        },
        {
          "id": 43632,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dabrafenib </span></span></span></p>"
        },
        {
          "id": 43633,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nilotinib</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following anticancer drugs act at the target shown in figure? </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/02/407.jpg\" style=\"height:226px; width:400px\" /></span></span></span></p>",
      "unique_key": "Q1287108",
      "question_audio": null,
      "question_video": null,
      "map_id": 36476,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Ribociclib</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Ribociclib</strong> is a <strong>selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6),</strong> which are <strong>enzymes </strong>that play a critical <strong>role in cell cycle progression. </strong>These <strong>kinases</strong> <strong>promote cell proliferation by phosphorylating</strong> and <strong>inactivating</strong> the <strong>retinoblastoma protein (Rb), </strong>which in turn allows the <strong>cell to pass </strong>through the<strong> G1 checkpoint</strong> and <strong>enter S phase</strong> of the <strong>cell cycle.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Inhibition of CDK4/6 </strong>by <strong>Ribociclib</strong> results in<strong> cell cycle arrest in the G1 phase</strong>, leading to <strong>inhibition of cell proliferation.</strong> This <strong>mechanism of action </strong>is particularly<strong> relevant in cancer cells</strong>, which often have <strong>aberrant regulation of the cell cycle and increased reliance on CDK4/6 activity to drive proliferation.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Ribociclib</strong> is approved for <strong>use in combination</strong> with other therapies for the treatment of<strong> estrogen receptor-positive</strong>, <strong>human epidermal growth factor receptor 2-negative (HR+/HER2-)</strong> <strong>advanced </strong>or <strong>metastatic breast cancer. </strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> <strong>Erlotinib</strong>: <strong>Erlotinib </strong>is a <strong>tyrosine kinase inhibitor</strong> that <strong>targets the epidermal growth factor receptor (EGFR) pathway</strong>. It works by <strong>blocking the activity of the EGFR protein, </strong>which is often <strong>overexpressed </strong>in certain types of <strong>cancer cells</strong> and contributes to <strong>tumor growth and spread</strong>. <strong>Erlotinib </strong>is primarily <strong>used </strong>to treat<strong> non-small cell lung cancer and pancreatic cancer. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> <strong>Dabrafenib</strong>:<strong> Dabrafenib </strong>is a<strong> selective inhibitor of the BRAF protein</strong>, which is a key component of the<strong> MAP kinase signalling</strong> <strong>pathway</strong>. This pathway is<strong> frequently mutated in certain types of cancer</strong>, including<strong> melanoma, and drives tumor growth</strong> <strong>and survival</strong>. Dabrafenib is<strong> used to treat advanced melanoma</strong> with<strong> BRAF V600E or V600K mutations</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> <strong>Nilotinib</strong>: Nilotinib is a<strong> tyrosine kinase inhibitor</strong> that targets the <strong>BCR-ABL protein,</strong> which is a <strong>fusion protein</strong> that drives the <strong>growth of chronic myelogenous leukemia (CML) cells. </strong>It works by<strong> blocking the activity</strong> of the<strong> BCR-ABL protein</strong>, leading to <strong>inhibition</strong> of <strong>cell proliferation and induction of cell death</strong>. <strong>Nilotinib </strong>is taken <strong>orally</strong> and is primarily used to treat<strong> CML.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Ribociclib </strong>is a<strong> targeted anticancer</strong> therapy that <strong>inhibits CDK4/6</strong>, key enzymes in <strong>cell cycle regulation</strong>. It is <strong>used to </strong>halt the <strong>progression of certain cancers</strong> by<strong> inducing cell cycle arrest at the G1 phase,</strong> thereby <strong>impeding the cancer cells</strong> <strong>from multiplying.</strong></span></span></span></p>",
      "correct_choice_id": 43631,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10918,
      "choices": [
        {
          "id": 43638,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">mTOR inhibitor</span></span></span></p>"
        },
        {
          "id": 43639,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Proteasome inhibitor</span></span></span></p>"
        },
        {
          "id": 43640,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Histone deacetylase inhibitors</span></span></span></p>"
        },
        {
          "id": 43641,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Protein tyrosine kinase inhibitor</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bortezomib is a drug used for treatment of multiple myeloma. What is the mechanism of action of this drug?</span></span></p>",
      "unique_key": "Q3428289",
      "question_audio": null,
      "question_video": null,
      "map_id": 36477,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Proteasome inhibitor</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Bortezomib</strong> is used to treat <strong>multiple myeloma.</strong> It works by<strong> inhibiting the activity of the proteasome,</strong> a <strong>large protein</strong> <strong>complex</strong> that is responsible for the<strong> degradation of many cellular proteins. </strong>Specifically,<strong> Bortezomib </strong>targets the<strong> 26S</strong> <strong>proteasome, </strong>which is involved in the<strong> degradation of ubiquitinated proteins.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">By<strong> inhibiting proteasome activity, Bortezomib</strong> interferes with the<strong> normal process of protein degradation</strong> and leads to the <strong>accumulation of misfolded or damaged proteins within the cell.</strong> This can cause<strong> cell cycle arrest, activation of</strong> <strong>apoptotic pathways,</strong> and ultimately, <strong>cell death.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"><strong> mTOR inhibitor</strong>: The <strong>mammalian target of rapamycin (mTOR)</strong> is a <strong>protein kinase</strong> that plays a key role in <strong>regulating cell</strong> <strong>growth and proliferation.</strong> <strong>Inhibition of mTOR activity </strong>can <strong>slow down</strong> or <strong>stop the growth of cancer cells.</strong> <strong>mTOR inhibitors</strong> such as <strong>temsirolimus and everolimus</strong> are used to <strong>treat renal cell carcinoma </strong>and <strong>breast cancer. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> <strong>Histone deacetylase inhibitors</strong>: HDAC enzymes are involved in the <strong>regulation of gene expression</strong>. By <strong>altering</strong> the <strong>acetylation status of histone proteins</strong>, <strong>HDAC inhibitors</strong> can induce changes in <strong>gene expression</strong> that can lead to <strong>cell cycle arrest,</strong> <strong>differentiation, or apoptosis.</strong> These drugs are<strong> used </strong>to treat various types of <strong>cancer, </strong>including<strong> lymphoma and leukaemia.</strong> Examples of <strong>HDAC inhibitors </strong>include<strong> vorinostat, romidepsin, and belinostat. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> <strong>Protein tyrosine kinase inhibitor</strong>:<strong> Protein tyrosine kinases (PTKs)</strong> are enzymes that play a role in<strong> cell signaling pathways</strong> and are often <strong>overexpressed or mutated in cancer cells</strong>. <strong>PTK inhibitors</strong> such as<strong> imatinib, dasatinib, and erlotinib</strong> <strong>target specific</strong> <strong>tyrosine kinases </strong>and <strong>inhibit their activity, </strong>leading to<strong> decreased cell proliferation and survival</strong>. These drugs are <strong>used to treat </strong>various <strong>types of cancer,</strong> including <strong>chronic myelogenous leukemia (CML) </strong>and some forms of<strong> lung cancer.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Bortezomib&#39;s </strong>role as a <strong>proteasome inhibitor</strong> makes it an<strong> effective drug </strong>in the treatment of <strong>multiple myeloma,</strong> by <strong>disrupting</strong> the <strong>regulated degradation of proteins</strong> and causing a <strong>build-up that is toxic to cancer cells.</strong></span></span></span></p>",
      "correct_choice_id": 43639,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10927,
      "choices": [
        {
          "id": 43674,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Erlotinib</span></span></span></p>"
        },
        {
          "id": 43675,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Regorafenib</span></span></span></p>"
        },
        {
          "id": 43676,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sorafenib</span></span></span></p>"
        },
        {
          "id": 43677,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vemurafenib</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following Tyrosine kinase inhibitors is used for the treatment of malignant melanoma? </span></span></span></p>",
      "unique_key": "Q9951085",
      "question_audio": null,
      "question_video": null,
      "map_id": 36478,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Vemurafenib</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Vemurafenib</span></strong><span style=\"font-size:12.0pt\"> is a <strong>tyrosine kinase inhibitor</strong> that specifically targets the<strong> BRAF V600E mutation</strong> in <strong>malignant melanoma.</strong> This mutation is <strong>present</strong> in a <strong>significant percentage of melanomas</strong> and contributes to the<strong> growth of cancer cells.</strong> By <strong>inhibiting the mutated BRAF</strong> <strong>kinase, vemurafenib</strong> can<strong> slow or stop </strong>the <strong>growth of the melanoma cells.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Erlotinib:</span></strong><span style=\"font-size:12.0pt\"> Erlotinib is used primarily for <strong>non-small cell lung carcinoma (NSCLC)</strong> and <strong>pancreatic cancer.</strong> It <strong>targets </strong>the <strong>epidermal growth factor receptor (EGFR),</strong> which is<strong> overexpressed or mutated </strong>in these cancers.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Regorafenib:</span></strong><span style=\"font-size:12.0pt\"> Regorafenib is used for <strong>colorectal carcinoma and gastrointestinal stromal tumors (GIST).</strong> It <strong>inhibits</strong> multiple <strong>protein kinases</strong> involved in<strong> tumor angiogenesis, oncogenesis, </strong>and the<strong> tumor microenvironment.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Sorafenib:</span></strong><span style=\"font-size:12.0pt\"> Sorafenib is used mainly for<strong> hepatocellular carcinoma (HCC) </strong>and also for<strong> renal cell carcinoma (RCC)</strong>. It <strong>targets</strong> <strong>multiple kinases</strong>, including those involved in <strong>angiogenesis and cell proliferation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Vemurafenib</strong> is<strong> used for </strong>the treatment of <strong>malignant melanoma.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Erlotinib </strong>is <strong>used for&nbsp; non-small cell carcinoma of lung and pancreatic carcinoma.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Regorafenib</strong> is used for<strong> colorectal carcinoma and GIST.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Sorafenib </strong>is used for <strong>hepatocellular carcinoma.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Indications of tyrosine kinase inhibitors</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/07/screenshot-2024-05-07-151648.png\" style=\"height:543px; width:900px\" /></span></strong></span></span></p>",
      "correct_choice_id": 43677,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}